MA42250A - Conjugués d'anticorps à cystéine modifiée - Google Patents
Conjugués d'anticorps à cystéine modifiéeInfo
- Publication number
- MA42250A MA42250A MA42250A MA42250A MA42250A MA 42250 A MA42250 A MA 42250A MA 42250 A MA42250 A MA 42250A MA 42250 A MA42250 A MA 42250A MA 42250 A MA42250 A MA 42250A
- Authority
- MA
- Morocco
- Prior art keywords
- conjugates
- cysteine
- modified
- modified antibody
- antibody conjugates
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/3069—Reproductive system, e.g. ovaria, uterus, testes, prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/526—CH3 domain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Cell Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pregnancy & Childbirth (AREA)
- Reproductive Health (AREA)
- Gynecology & Obstetrics (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Plural Heterocyclic Compounds (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Abstract
L'invention concerne de nouveaux conjugués constitués d'un agent de liaison cellulaire et d'un agent cytotoxique, où l'agent de liaison cellulaire (cba) est lié de manière covalente à l'agent cytotoxique par l'intermédiaire d'une cys modifiée, telle qu'une cys modifiée au niveau du domaine ch3 de la chaîne lourde, à une position correspondant à la position 442 en numérotation eu/ou (ou c442) sur un cba de type anticorps. L'invention porte également sur des méthodes de préparation des conjugués de la présente invention. L'invention concerne, en outre, une composition et des méthodes utilisables pour inhiber une croissance cellulaire anormale ou traiter un trouble prolifératif chez le mammifère à l'aide des conjugués de l'invention.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562186254P | 2015-06-29 | 2015-06-29 | |
| US201662338245P | 2016-05-18 | 2016-05-18 | |
| US15/195,269 US10898579B2 (en) | 2015-06-29 | 2016-06-28 | Conjugates of cysteine engineered antibodies |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MA42250A true MA42250A (fr) | 2018-05-02 |
| MA42250B1 MA42250B1 (fr) | 2020-11-30 |
Family
ID=56409216
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA42250A MA42250B1 (fr) | 2015-06-29 | 2016-06-28 | Conjugués d'anticorps à cystéine modifiée |
Country Status (24)
| Country | Link |
|---|---|
| US (2) | US10898579B2 (fr) |
| EP (2) | EP3769787A1 (fr) |
| JP (4) | JP6843080B2 (fr) |
| KR (1) | KR20180021176A (fr) |
| CN (2) | CN113769108A (fr) |
| AR (1) | AR106013A1 (fr) |
| AU (2) | AU2016285929B2 (fr) |
| CA (1) | CA2988806A1 (fr) |
| CY (1) | CY1123606T1 (fr) |
| DK (1) | DK3313845T3 (fr) |
| ES (1) | ES2832527T3 (fr) |
| HK (1) | HK1254782A1 (fr) |
| HR (1) | HRP20201790T1 (fr) |
| HU (1) | HUE052616T2 (fr) |
| LT (1) | LT3313845T (fr) |
| MA (1) | MA42250B1 (fr) |
| MD (1) | MD3313845T2 (fr) |
| PL (1) | PL3313845T3 (fr) |
| PT (1) | PT3313845T (fr) |
| RS (1) | RS61050B1 (fr) |
| RU (1) | RU2733740C2 (fr) |
| SI (1) | SI3313845T1 (fr) |
| TW (2) | TW202146057A (fr) |
| WO (1) | WO2017004025A1 (fr) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PT3313884T (pt) | 2015-06-29 | 2021-02-25 | Immunogen Inc | Anticorpos anti-cd123 e conjugados e derivados dos mesmos |
| EP4335851A3 (fr) | 2015-11-25 | 2024-06-05 | ImmunoGen, Inc. | Formulations pharmaceutiques et leurs procédés d'utilisation |
| CN116813690A (zh) | 2016-11-23 | 2023-09-29 | 伊缪诺金公司 | 苯并二氮䓬衍生物的选择性磺化 |
| DK3558391T3 (da) | 2016-12-23 | 2022-05-09 | Immunogen Inc | Immunkonjugater med adam9 som mål og fremgangsmåder til anvendelse deraf |
| WO2018183494A1 (fr) | 2017-03-31 | 2018-10-04 | Immunogen, Inc. | Conjugués anticorps-médicament ciblant cd19 |
| MA50195A (fr) | 2017-09-22 | 2020-07-29 | Immunogen Inc | Séparation d'anticorps à chaîne triple légère à l'aide d'une chromatographie à échange de cations |
| BR112020004126A2 (pt) | 2017-09-29 | 2020-09-08 | Daiichi Sankyo Company, Limited | conjugado anticorpo-derivado de pirrolbenzodiazepina |
| TW202029980A (zh) | 2018-10-26 | 2020-08-16 | 美商免疫遺傳股份有限公司 | Ｅ ｐ Ｃ Ａ Ｍ 抗體、可活化抗體及免疫偶聯物以及其用途 |
| AU2019370291A1 (en) | 2018-10-30 | 2021-05-20 | Immunogen, Inc. | Methods of treatment using anti-CD123 immunoconjugates |
| US10851117B2 (en) | 2018-11-12 | 2020-12-01 | Immunogen, Inc. | Methods of preparing cytotoxic benzodiazepine derivatives |
| AU2019379418A1 (en) | 2018-11-14 | 2021-06-03 | Daiichi Sankyo Company, Limited | Anti-CDH6 antibody-pyrrolobenzodiazepine derivative conjugate |
| KR20220022112A (ko) * | 2019-03-21 | 2022-02-24 | 이뮤노젠 아이엔씨 | 세포-결합 제제-약물 콘쥬게이트를 준비하는 방법 |
| JPWO2020196474A1 (fr) | 2019-03-25 | 2020-10-01 | ||
| KR20210141630A (ko) | 2019-03-25 | 2021-11-23 | 다이이찌 산쿄 가부시키가이샤 | 항 her2 항체-피롤로벤조디아제핀 유도체 콘주게이트 |
| JPWO2020196712A1 (fr) | 2019-03-27 | 2020-10-01 | ||
| WO2020223351A1 (fr) | 2019-04-29 | 2020-11-05 | Immunogen, Inc. | Combinaisons thérapeutiques comprenant des immunoconjugués anti-cd123 |
| AU2021338014A1 (en) | 2020-09-02 | 2023-03-09 | Daiichi Sankyo Company, Limited | Novel endo-β-N-acetylglucosaminidase |
| TW202237135A (zh) | 2021-01-13 | 2022-10-01 | 紀念斯隆凱特琳癌症中心 | 抗體-吡咯并苯并二氮呯衍生物結合物 |
| TW202334238A (zh) | 2021-11-30 | 2023-09-01 | 日商第一三共股份有限公司 | 蛋白酶分解性遮蔽抗體 |
Family Cites Families (41)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5208020A (en) | 1989-10-25 | 1993-05-04 | Immunogen Inc. | Cytotoxic agents comprising maytansinoids and their therapeutic use |
| ES2149768T3 (es) | 1992-03-25 | 2000-11-16 | Immunogen Inc | Conjugados de agentes enlazantes de celulas derivados de cc-1065. |
| GB9422383D0 (en) * | 1994-11-05 | 1995-01-04 | Wellcome Found | Antibodies |
| NZ517772A (en) | 1999-11-24 | 2004-03-26 | Immunogen Inc | Cytotoxic agents comprising taxanes and their therapeutic use |
| US6441163B1 (en) | 2001-05-31 | 2002-08-27 | Immunogen, Inc. | Methods for preparation of cytotoxic conjugates of maytansinoids and cell binding agents |
| US6716821B2 (en) | 2001-12-21 | 2004-04-06 | Immunogen Inc. | Cytotoxic agents bearing a reactive polyethylene glycol moiety, cytotoxic conjugates comprising polyethylene glycol linking groups, and methods of making and using the same |
| US6756397B2 (en) | 2002-04-05 | 2004-06-29 | Immunogen, Inc. | Prodrugs of CC-1065 analogs |
| CA2494074A1 (fr) | 2002-08-02 | 2004-02-12 | Immunogen, Inc. | Agents cytotoxiques renfermant des nouveaux taxanes puissants et utilisation therapeutique de ceux-ci |
| DE60336149D1 (de) | 2002-08-16 | 2011-04-07 | Immunogen Inc | Vernetzer mit hoher reaktivität und löslichkeit und ihre verwendung bei der herstellung von konjugaten für die gezielte abgabe von kleinmolekularen arzneimitteln |
| HUE026914T2 (en) | 2002-11-07 | 2016-08-29 | Immunogen Inc | Anti-CD33 antibodies and a method of treating acute myeloid leukemia |
| US8088387B2 (en) | 2003-10-10 | 2012-01-03 | Immunogen Inc. | Method of targeting specific cell populations using cell-binding agent maytansinoid conjugates linked via a non-cleavable linker, said conjugates, and methods of making said conjugates |
| US7276497B2 (en) | 2003-05-20 | 2007-10-02 | Immunogen Inc. | Cytotoxic agents comprising new maytansinoids |
| AU2005218642B2 (en) | 2004-03-02 | 2011-04-28 | Seagen Inc. | Partially loaded antibodies and methods of their conjugation |
| BRPI0510883B8 (pt) | 2004-06-01 | 2021-05-25 | Genentech Inc | composto conjugado de droga e anticorpo, composição farmacêutica, método de fabricação de composto conjugado de droga e anticorpo e usos de uma formulação, de um conjugado de droga e anticorpo e um agente quimioterapêutico e de uma combinação |
| ES2579805T3 (es) | 2004-09-23 | 2016-08-16 | Genentech, Inc. | Anticuerpos y conjugados modificados por ingeniería genética con cisteína |
| EP1817341A2 (fr) | 2004-11-29 | 2007-08-15 | Seattle Genetics, Inc. | Anticorps et immunoconjugues mis au point |
| US8008453B2 (en) | 2005-08-12 | 2011-08-30 | Amgen Inc. | Modified Fc molecules |
| CN103030696B (zh) | 2006-05-30 | 2016-09-28 | 健泰科生物技术公司 | 抗体和免疫偶联物及其用途 |
| NZ614857A (en) | 2007-03-29 | 2015-04-24 | Genmab As | Bispecific antibodies and methods for production thereof |
| BRPI0911442A2 (pt) | 2008-04-30 | 2019-03-12 | Immunogen, Inc. | conjugados potentes e ligantes hidrofílicos |
| KR20210100223A (ko) | 2008-04-30 | 2021-08-13 | 이뮤노젠 아이엔씨 | 가교제 및 그 용도 |
| BRPI1008749B8 (pt) * | 2009-02-05 | 2021-05-25 | Immunogen Inc | compostos derivados de benzodiazepina, seus conjugados, composição farmacêutica, seu uso e seus processos de preparação |
| US8431416B2 (en) * | 2009-04-01 | 2013-04-30 | Becton, Dickinson And Company | Reactive heterocycle-substituted 7-hydroxycoumarins and their conjugates |
| US20120213705A1 (en) | 2009-06-22 | 2012-08-23 | Medimmune, Llc | ENGINEERED Fc REGIONS FOR SITE-SPECIFIC CONJUGATION |
| WO2011092838A1 (fr) | 2010-01-29 | 2011-08-04 | 株式会社フォーサイド・ドット・コム | Système de partage de contenu et procédé de partage de contenu |
| KR101580713B1 (ko) | 2010-02-24 | 2015-12-29 | 이뮤노젠 아이엔씨 | 엽산염 수용체 1 항체와 면역접합체 및 이들의 용도 |
| CN102971012B (zh) | 2010-03-12 | 2016-05-04 | 伊缪诺金公司 | Cd37结合分子及其免疫缀合物 |
| BR112012026766B1 (pt) | 2010-04-20 | 2021-11-03 | Genmab A/S | Métodos in vitro para gerar um anticorpo igg heterodimérico, para a seleção de um anticorpo biespecífico, vetor de expressão, anticorpo igg heterodimérico, composição farmacêutica, e, uso de um anticorpo igg heterodimérico |
| SG189929A1 (en) | 2010-10-29 | 2013-06-28 | Immunogen Inc | Novel egfr-binding molecules and immunoconjugates thereof |
| EA201390575A1 (ru) | 2010-10-29 | 2014-01-30 | Иммьюноджен, Инк. | Неантагонистические egfr-связывающие молекулы и их иммуноконъюгаты |
| EP3666289A1 (fr) * | 2011-02-15 | 2020-06-17 | ImmunoGen, Inc. | Dérivés de benzodiazépine cytotoxique |
| WO2014134483A2 (fr) | 2013-02-28 | 2014-09-04 | Immunogen, Inc. | Conjugués comprenant des agents de liaison cellulaire (cba) et des agents cytotoxiques |
| WO2014134457A2 (fr) | 2013-02-28 | 2014-09-04 | Immunogen, Inc. | Conjugués comprenant des agents de liaison cellulaire (cba) et des agents cytotoxiques |
| US9901647B2 (en) | 2013-02-28 | 2018-02-27 | Immunogen, Inc. | Conjugates comprising cell-binding agents and cytotoxic agents |
| JP6685924B2 (ja) * | 2014-04-11 | 2020-04-22 | メディミューン，エルエルシー | システイン操作抗体を含むコンジュゲート化合物 |
| EP3157961A4 (fr) * | 2014-06-20 | 2018-01-24 | BioAlliance C.V. | Conjugués anticorps anti-cd22-médicament et leurs méthodes d'utilisation |
| AU2015276821A1 (en) * | 2014-06-20 | 2017-01-12 | Abgenomics International Inc. | Anti-folate receptor aplha (FRA) antibody-drug conjugates and methods of using thereof |
| BR112016029588A2 (pt) * | 2014-06-20 | 2017-08-22 | Abgenomics Int Inc | conjugados de anticorpo-fármaco para her2 |
| JP2017526682A (ja) * | 2014-09-02 | 2017-09-14 | イミュノジェン， インコーポレイテッド | 抗体薬物複合体組成物の製剤化方法 |
| MA41645A (fr) | 2015-03-04 | 2018-01-09 | Abbvie Stemcentrx Llc | Anticorps issus de génie génétique spécifiques au site et méthodes d'utilisation |
| PT3313884T (pt) | 2015-06-29 | 2021-02-25 | Immunogen Inc | Anticorpos anti-cd123 e conjugados e derivados dos mesmos |
-
2016
- 2016-06-28 RU RU2017144859A patent/RU2733740C2/ru active
- 2016-06-28 EP EP20182141.0A patent/EP3769787A1/fr active Pending
- 2016-06-28 WO PCT/US2016/039796 patent/WO2017004025A1/fr active Application Filing
- 2016-06-28 MD MDE20180452T patent/MD3313845T2/ro unknown
- 2016-06-28 HU HUE16738322A patent/HUE052616T2/hu unknown
- 2016-06-28 CN CN202111168673.4A patent/CN113769108A/zh active Pending
- 2016-06-28 PT PT167383223T patent/PT3313845T/pt unknown
- 2016-06-28 CN CN201680038492.0A patent/CN107708810B/zh active Active
- 2016-06-28 EP EP16738322.3A patent/EP3313845B1/fr active Active
- 2016-06-28 JP JP2017568292A patent/JP6843080B2/ja active Active
- 2016-06-28 DK DK16738322.3T patent/DK3313845T3/da active
- 2016-06-28 ES ES16738322T patent/ES2832527T3/es active Active
- 2016-06-28 KR KR1020187002729A patent/KR20180021176A/ko not_active Application Discontinuation
- 2016-06-28 CA CA2988806A patent/CA2988806A1/fr active Pending
- 2016-06-28 PL PL16738322T patent/PL3313845T3/pl unknown
- 2016-06-28 MA MA42250A patent/MA42250B1/fr unknown
- 2016-06-28 SI SI201630977T patent/SI3313845T1/sl unknown
- 2016-06-28 RS RS20201354A patent/RS61050B1/sr unknown
- 2016-06-28 LT LTEP16738322.3T patent/LT3313845T/lt unknown
- 2016-06-28 AU AU2016285929A patent/AU2016285929B2/en active Active
- 2016-06-28 US US15/195,269 patent/US10898579B2/en active Active
- 2016-06-29 TW TW110132303A patent/TW202146057A/zh unknown
- 2016-06-29 AR ARP160101972A patent/AR106013A1/es unknown
- 2016-06-29 TW TW105120514A patent/TWI740833B/zh active
-
2018
- 2018-10-30 HK HK18113828.1A patent/HK1254782A1/zh unknown
-
2020
- 2020-09-08 US US17/014,404 patent/US20210085800A1/en active Pending
- 2020-11-09 HR HRP20201790TT patent/HRP20201790T1/hr unknown
- 2020-11-10 CY CY20201101058T patent/CY1123606T1/el unknown
-
2021
- 2021-02-19 JP JP2021025322A patent/JP2021088581A/ja active Pending
-
2022
- 2022-03-31 AU AU2022202208A patent/AU2022202208A1/en active Pending
- 2022-08-15 JP JP2022129205A patent/JP7441281B2/ja active Active
-
2024
- 2024-02-16 JP JP2024021646A patent/JP2024067036A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MA42250A (fr) | Conjugués d'anticorps à cystéine modifiée | |
| MA46452B1 (fr) | Composés de benzo[b]thiophéne en tant qu'agonistes de sting | |
| MA46708B1 (fr) | Anticorps anti-pd1 et leurs utilisations | |
| MA38496A1 (fr) | Molécules biologiquement actives, leurs conjugués, et utilisations thérapeutiques | |
| MA34286B1 (fr) | Compositions pharmaceutiques et procédés pour les fabriquer | |
| MA44146B1 (fr) | Combinaison d'anticorps anti-pd-1 et d'anticorps bispécifiques anti-cd20/anti-cd3 pour traiter le cancer | |
| PH12017500358A1 (en) | Cytotoxic benzodiazepine derivatives | |
| BR112018075626A2 (pt) | anticorpos anti-b7-h3 e conjugados de fármaco anticorpo | |
| MA45280B1 (fr) | Conjugués anticorps-médicament à base d'éribuline et leurs procédés d'utilisation | |
| SG195172A1 (en) | Novel maytansinoid derivatives with peptide linker and conjugates thereof | |
| MA39313A1 (fr) | Anticorps anti-egfrviii et leurs utilisations dans le traitement de divers cancers | |
| DK1537878T3 (da) | Immunpotenserende sammensætninger | |
| MX346635B (es) | Derivados citotoxicos de la benzodiazepina. | |
| MX2019013690A (es) | Conjugados de farmaco-proteina con ciclodextrina. | |
| MA35035B1 (fr) | Anticorps polypeptidiques qui antagonisent les cd40 | |
| EA202091217A1 (ru) | Конъюгат аналога тубулизина с разветвленными линкерами | |
| MA42811A (fr) | Dérivés d'indole monosubstitués ou disubstitués utilisés en tant qu'inhibiteurs de la réplication du virus de la dengue | |
| BR112018075630A2 (pt) | anticorpos anti-cd98 e conjugados de fármaco de anticorpo | |
| MA39254B2 (fr) | Anticorps stables à affinité élevée et agrégatifs à base de domaines viraux vl et de dérivé de vhh | |
| EA201070826A1 (ru) | Антитела против pcrv | |
| FR3070831B1 (fr) | Procede de preparation d'une composition a base de proteines de legumineuses | |
| WO2019078697A3 (fr) | Anticorps anti-cd3 et composition pharmaceutique destinée au traitement du cancer, contenant ledit anticorps | |
| MA32029B1 (fr) | Vaccins contre la malaria | |
| AU2020357395A8 (en) | Bicyclic compound and use thereof | |
| MA38848A1 (fr) | Anticorps anti-prlr et utilisations associées |